科濟藥業-B(02171.HK):於2022年ASH年會上呈列的澤沃基奧侖賽注射液的研究成果更新
格隆匯12月12日丨科濟藥業-B(02171.HK)發佈公吿,在2022年美國血液學會(“ASH”)年會上,公司展示了一篇關於澤沃基奧侖賽注射液(zevorcabtagene autoleucel,研發代號: CT053,一種針對BCMA的自體CAR-T候選產品)在中國復發╱難治多發性骨髓瘤患者中的II期臨牀研究(LUMMICAR STUDY 1)的研究結果的海報。這份海報首次報吿了LUMMICAR STUDY 1的關鍵性II期安全和療效資料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.